Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.
- Published In:
- Expert opinion on drug safety, 24(8), 959-967 (2025)
- Authors:
- Chen, Han(3), Ding, Yuhang, Shan, Yongqi
- Database ID:
- RPEP-10381
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10381APA
Chen, Han; Ding, Yuhang; Shan, Yongqi. (2025). Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.. Expert opinion on drug safety, 24(8), 959-967. https://doi.org/10.1080/14740338.2025.2468860
MLA
Chen, Han, et al. "Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.." Expert opinion on drug safety, 2025. https://doi.org/10.1080/14740338.2025.2468860
RethinkPeptides
RethinkPeptides Research Database. "Post-marketing safety monitoring of tirzepatide: a pharmacov..." RPEP-10381. Retrieved from https://rethinkpeptides.com/research/chen-2025-postmarketing-safety-monitoring-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.